Description

Sign up or Log In

Sign up for free guest access to view investment ideas with a 45-day delay and read the full report.

Log in to read the full report.

show sort by

You are not eligible to view 19 messages. To gain access to more recent message posts signup free for membership.

#	AUTHOR DATE SUBJECT
37	member 8/17/22 11:39AM Valuation
I have this trading at <8x '23 eps and 13x '23 FCF at current prices. Do you still like this name despite the recent regulatory news? 1 view available tags
36	member 6/21/22 2:22PM Marietta
Hey Poms, Nice win on this one. Do you have any opinion on the stock following today's SCOTUS ruling? This is as optically cheap as it's been a while, but obviously there are concerns about patient mix and... login to read the rest view available tags
34	member 11/06/19 3:17PM Re: Very good quarterly results 33
A good premise to start with is that DaVita is a very stable growing business. This quarter and the guidance should be pretty reflective of go-forward performance; 2.5-3.0% volume ex-acquisitions with firm pricing now that... login to read the rest 2 view available tags
32	member 8/28/19 8:22AM Re: Re: Tender results 31
Yes i am aware the results are very accretive. The lower price in the "long run" is clearly a benefit. I can't figure out how a quant fund would have accumulated enough (or any stock) during... login to read the rest view available tags
29	member 7/09/19 8:27AM Trump aims to shake up kidney market
Very interesting idea, especially with deal closure risk off the table. I realize there has always been a regulatory/reimbursement risk, which you addressed in your initial write-up. Anyone have thoughts on the potential new round of headlines? Regulation view available tags
27	member 6/19/19 4:57PM Re: Ftc approval 26
This probably has a lot to do with it, so still some uncertainty around the close: https://www.denverpost.com/2019/06/19/colorado-davita-unitedhealth-group-merger/ Agree this should have moved the stock more, and I believe would have in the absence of the suit. view available tags
24	member 6/07/19 12:17PM Re: Re: Re: Re: Re: Re: Re: Re: Re: Re: Very cheap 23
On Buyback Price: headline is that they have to wait for the DMG sale to start buying again, so it's the post-sale stock price that likely matters DaVita is levered to 4.52x vs. a stated target... login to read the rest view available tags
20	member 6/04/19 3:16PM Re: Re: Re: Re: Re: Re: Very cheap 19
I agree that DVA (still long) seems incredibly cheap for the reasons you mentioned. On DMG, the firms remain tight-lipped and the deal not closing seems largely priced in. The only comment I've seen recently was a parenthetical /... login to read the rest view available tags
12	member 11/09/18 11:38AM Re: Regulatory Hangover ? 11
I think the regulatory impact on shares isn't new and has been priced in throughout DaVita's existence; the dialysis comp set has typically traded at an attractive cash flow yield for its growth profile. Especially with California... login to read the rest 1 view available tags
11	member 10/25/18 8:26AM Regulatory Hangover ?
Poms - thanks for the write-up. I was wondering what your thoughts are on the argument that in a Prop 8 win or lose scenario, DVA and peers will trade with a regulatory overhang moving forward,... login to read the rest view available tags
9	member 9/09/18 9:53PM Re: Re: Re: Switching to medicare 4
On the "stable" pricing and "less bad" funadmental backdrop, I think we're really talking about economics per treatment, which I'd view as follows. Revenue Dynamics Commercial Pay, 1/3 of revenue: management has guided 'stable' without any quantiative... login to read the rest view available tags
8	member 9/09/18 9:35PM Re: Re: Moral obligation to take losses? 7
In an attempt to address mko2016 (and others) on legislation: I wouldn't say this a prediction of a good legislative outcome; it's more weighing the potentialities on either side against each other and comparing that... login to read the rest view available tags
7	member 9/07/18 2:21PM Re: Moral obligation to take losses? 6
I broadly agree with this thesis. The public isn't shedding any tears because insurance companies lose money on dialysis coverage and i wouldn't expect them to if dva makes less in reimbursement. The system more view available tags
5	member 9/07/18 11:47AM Risk!
The risk from the CA ballot is far greater than you portray, at least in our minds. If the ballot in CA is successful and a cap is put on the dialysis industry, then it could catch... login to read the rest 2 view available tags
4	member 9/07/18 10:47AM Re: Re: Switching to medicare 2
I do not think there is more headline risk re the AKF, but I do think there is still risk long term. I understand AKF paying for patients' med supp plan given Medicare doesn't have... login to read the rest 2 view available tags
3	member 9/07/18 10:05AM Re: Switching to medicare 1
I think you'll find there are a many different explanations for why someone wouldn't automatically switch, but i think they all come back to the cost/benefit of the patient. Some have coverage from their union... login to read the rest 1 view available tags
2	member 9/07/18 10:03AM Re: Switching to medicare 1
Medicare doesn't have an OOP max and dialysis will bleed you dry. MA does have OOP max, but they won't take you so you have to go FFS. Patients could be on their employer plan 2 view available tags
1	member 9/07/18 9:47AM Switching to medicare
Good writeup, thanks. Question: since all dialysis patients have the option of immediately switching to Medicare, why doesn't everyone do that? Why would people voluntarily pay much higher commercial premiums and deductibles? view available tags

load more messages

			2010	2011
Price:	1.44	EPS	-$0.30	-$0.10
Shares Out. (in M):	189	P/E	NM	NM
Market Cap (in $M):	272	P/FCF	NM	NM
Net Debt (in $M):	0	EBIT	-57	-30
TEV (in $M):	272	TEV/EBIT	NM	NM
Borrow Cost:	NA

Description

Sign up or Log In

Sign up for free guest access to view investment ideas with a 45-day delay and read the full report. Log in to read the full report.

Sign up for free guest access to view investment ideas with a 45-day delay and read the full report.

Log in to read the full report.